Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving selumetinib and erlotinib hydrochloride together
works in treating patients with locally advanced or metastatic pancreatic cancer that is
refractory to chemotherapy. Selumetinib and erlotinib hydrochloride may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth.